CAR-T cells are the T-cells that have been genetically engineered to produce an artificial T-cell receptor for use in immunotherapy. Right now, there are more than 2300 clinical trials concerned with CAR-T cells.
It can be targeted to specific proteins.
The CAR-T cells are used for cancer immunotherapy. The modified T-cells can recognize cancer cells and destroy them.
The 3 top CAR-T cells targets are:
- Acute lymphoblastic leukemia (ALL)
- Diffuse large B-cell lymphoma (DLBCL)
- Multiple myeloma (MM)
Right now, there are more than 2300 clinical trials concerned with CAR-T cells.
The latest news on Car-T cells
Bristol Myers Squibb and bluebird bio announced to present updated positive results from pivotal, Phase 2 KarMMa study of Ide-cel in relapsed and refractory multiple myeloma patients as the oral presentation at American Society of Clinical Oncology 2020 (ASCO20). Furthermore, the same data will be announced during the virtual edition of the 25th European Hematology Association Annual Congress.
Soon, the Autolus Therapeutics plc is going to present new data on the AUTO3 clinical trial. This biopharmaceutical company is developing next-generation programmed T-cell therapies in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). The data will be also presented on ASCO20.
Atara Biotherapeutics Inc., a pioneer in T-cell immunotherapy announced additional preclinical data on ATA2271, a next-generation autologous CAR-T cell immunotherapy against malignant pleural disease and mesothelioma, non-small cell lung cancer and breast cancer.